-
Esta página já teve 134.685.319 acessos - desde 16 maio de 2003. Média de 24.668 acessos diários
home | entre em contato
 

Endocrinologia/Glândulas

Outros hormônios que facilitam a secreção de GH

10/04/2006

 

Danielle Fernanda de Campos Morais

Trabalho de Conclusão de Curso

Faculdade UNIGRANRIO

2006

 

Fragmento do trabalho:

 

A administração aguda de glicocorticóides estimula a secreção de GH, todavia administração crônica do mesmo inibe a secreção. Três horas após administração aguda de glicocorticóide, o nível de GH é elevado e assim se mantém por duas horas. Contudo, uma exposição muito elevada a corticóides, em pacientes com retardo de crescimento e Doença de Cushing, foi relacionada a decréscimo de GH sérico e reduzido GH hipofisário nas proximidades do adenoma. Quando administrados a pacientes normais, doses de glicocorticóides inibiram o estimulo de GHRH para secreção de GH de forma similar à vista na Síndrome de Cushing. Além disso, cortisol antagoniza a ação periférica do GH.

 

Os níveis de GH estão reduzidos em pacientes hipertireoideos, mas tornam-se normais quando os pacientes voltam a ser eutireoideos, sugerindo que o hormônio da tireóide suprime a secreção de GH. Elevados níveis circulantes de esteróides gonadais, observado durante a puberdade, devem também ser responsáveis por contabilizar com elevados níveis de GH puberal. O estrogênio estimula taxas de secreção de GH e testosterona aumenta a massa secretória de GH com resultante indução de IGF-I.

                                                                                                                                

O TRH não estimula a secreção de GH em indivíduos normais, mas induz a sua secreção em aproximadamente 70% de pacientes acromegálicos.

 

Respostas divergentes de GH ao estímulo de TRH são vistas em pacientes com doença hepática, renal, secreção ectópica de GHRH por tumores, anorexia nervosa e depressão. O TRH estimula, provavelmente, em humanos, a secreção de GH somente em alguns experimentos e em condições onde estejam presentes alterações como acromegalia, diabetes tipo um, insuficiência hepática ou renal, mas não usualmente em pacientes saudáveis. Ele estimula a secreção de GH em aproximadamente um terço dos pacientes com acromegalia.

                                                                                                                     

A calcitonina, hormônio produzido na região medular ou nas células C da glândula tireóide, inibe a atividade osteoclástica e diminui a depuração renal de cálcio e fosfato. Ela impõe diversos efeitos endocrinológicos, como a inibição da secreção de gastrina, a liberação basal e ao estímulo de insulina e as respostas hipofisárias de TSH e LH ao TRH e LHRH, respectivamente. Em ratos, a administração de calcitonina reduz a secreção de 24 horas de GH e as respostas de GH e ao GHRH. Em humanos, a injeção intramuscular induz respostas de GH a estímulos hipotalâmicos assim como a L’arginina e a hipoglicemia induzida por insulina. [12, 13, 14, 15, 16]

 

REFERÊNCIAS BIBLIOGRÁFICAS

 

1 - Bronstein MD. Reposição de GH na “Somatopausa”: Solução ou Problema? Arqu Bras Endocrinol Metab 2003; 47/4: 323-330.

2 - Liberman L, Cukiert A. Fisiologia e fisiopatologia do hormônio do crescimento. 1ª ed.Lemos Editorial. São Paulo (SP); 2004.

3 - Toogood AA, Shalet SM. Conflicts with the somatopause. Growth Hormone and IGF Research 1998; 8(Suppl. A): 47-54.

4 - Lamberts SWJ. The Somatopause: To Treat or Not to Treat? Horm Res 2000; 53(Suppl 3): 42-43.

5 - Khorram O. Use of Growth Hrmone and Growth Hormone Secretagogues in Aging:

 

Help or Harm. Clinical Obstetrics and Gynecology 2001; 44: 893-901.

 

6 - Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocrine Rev.1993; 14: 20-39.

7 -  Larsen PR, Kronenberg HM, Melmed S, Polonsky KS. Williams Textbook of Endocrinology. 10ª ed. Philadelphia: Saunders, 2003. P.219-243, 1297-1298.

8 – Vilar L, Castellar E, Moura E, Leal E, Machado AC, Teixeira L, Campos R. Endocrinologia Clínica. 2ªed. Rio de Janeiro: Medsi. 2001. P. 46-49.

9 –  Datani M, Preece M. Growth hormone deficiency and related disorders: insights into causation, diagnosis, and treatment. The Lancet. 2004; 363: 1977-1984.

10 - Van Cauter E,  Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep 1998; 21: 553-566.

11 - Van Cauter E. Slow wave sleep and release of growth hormon. JAMA  2000; 284:2717-2718.

12 - Giustina A, Veldhuis JD. Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human. Endocrine Reviews 1998; 19(6): 717–797.

13 – Broglio F, et al. Natural and Synthetic Growth Hormone Secretagogues: Do They Have Therapeutic Potential? Trat Endocrinol 2003; 2(3): 153-163.

14 - Giustina A, Doga M, Bresciani E, Bussi AR, Chiesa L, Misitano V, Giustina G. Effect of glucocorticoids on the paradoxical growth hormone response to thyrotropin-releasing hormone in patients with acromegaly. Metabolism 2005; 44: 379–383.

15 - Valentini U, Cimino A, Rotondi A, Pelizzari R, Giustina A, Marchetti C, Romanelli G. Growth hormone response to thyrotropin releasing hormone and placebo in a group of insulin-dependent diabetic patients. J Endocrinol Invest 1989; 12: 643–646.

16 - Czernichow P, Dauzet MC, Broyer M, Rappaport R. Abnormal TSH, PRL and GH responses to TSH-releasing factor in chronic renal failure. J Clin Endocrinol Metab 1976; 43:630–637.

17 - Johansson JO, Fowelin J, Landin K, et al. Growth hormone-deficient adults are insulin-resistant. Metabolism 1995. 44: 1126-1129.

18 - Iranmesh A, Lizzaralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J  Clin Endocrinol Metab 1991; 73: 1081-1088.

19 - Rosen T, Hansson T, GRanhed H, Szues J, Bengtsson BA. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol 1993; 129: 201-206.

20 – López-Fernández J, Sánchez-Franco F, Velasco B, Tolón RM, Pazos F, Cacicedo L. Growth hormone induces Somatostatin and Insulin-Like Growth Factor I Gene Expression in the Cerebral Hemispheres of Aging Rats. Endocrinology 1996; 137 (10): 4384-4391.

21 - Corpas E, Harman SM, Blackman MR. Serum IGF-binding protein-3 is related to IGF-I, but not to spontaneous GH release, in healthy old men. Horm Metab Res 1992; 24: 543-545.

22 – Merimee TJ, Danghaday WL. Growth hormone binding protein II: studies in pygmies and normal statured subjects. J Clin Endocrinol Metab 1990; 71: 1183-1188.

23 – Baumann G, Amburn K. Regulation of plasma growth hormone binding proteins in healthy and disease. Metabolism 1989; 120: 121-128.

24 - Donahue LR, Hunter SJ, Sherblom AP, Rosen C. Age related changes in serum insulin-like growth factor-binding proteins in women. J Clin Endocrinol Metab 1990; 71: 575-579.

25 – Ceda GP, Dall´aglio E, Magnacavallo A, Vargas N, Fontana V,  Maggio M, Valenti G, Lee P, Hintz RL, Hoffman AR. The Insulin-Like Growth Factor Axis and Plasma Lipid Levels in the Elderly. 1998; 83(2): 499-502.

26 – Baumgartner RN, Koehler KM. Epidemiology of sarcopenia among the elferly in New Mexico. Am J Epidemiol 1998, 147: 755-763.

27 – Forbes GB. Body composition: overview. J Nutr 1999; 129(5): 270-272.

28 - Toogood AA, Jones J, O´Neill PA, Thorner MO, Shalet SM. The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease. Clin Endocrinol 1997.

29 – Rosen JC. Growth Hormone and Aging. Endocrine 2000; 12(2): 197-201.

30 - Thompson JL, Butterfield GE, Gylfadottir UK, Yesavage J, Marcus R, Hintz RL, Pearman A, Hoffman AR. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J Clin Endocrinol Metab 1998;  83:1477–1484.

31 - Shetty KR, Duthie EH. Anterior pituitary function and growth hormone use in the elderly. Endocrinol Metab Clin North Am 1995; 24: 213–231.

32 - Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RG. Effects of single nightly injections of growth hormonereleasing hormone (GHRH 1–29) in healthy elderly men 1997;  Metab Clin Exp 46: 89–96.

33 - Khorram O, Laughlin GA, Yen SSC. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1–29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997; 82: 1472–1479.

34 - Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GA, Schambelan M, Grunfeld C. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996; 124 :708–716.

35 - Thompson JL, Butterfield GE, Marcus R, Hintz RL, Van Loan M, Ghiron L, Hoffman AR. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab 1995; 80: 1845–1852.

36 - Borst SE, Millard WJ, Lowenthal DT. Growth hormone, exercise, and aging: the future of therapy for the frail elderly. J Am Geriatr Soc 1994; 42: 528–535.

37 - Welle S, Thornton C, Statt M, McHenry B.  Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein in healthy subjects over 60 years old. J Clin Endocrinol Metab 1996; 81: 3239–3243.

38 - Taaffe DR, Pruitt L, Reim J, Hintz RL, Butterfield G, Hoffman AR, Marcus

R. Effect of recombinant human growth hormone on the muscle response to resistance to exercise in elderly men. J Clin Endocrinol Metab 1994; 79: 1361–1366.

39 - Nicklas BJ, Ryan AJ, Treuth MM, Harman SM, Blackman MR, Hurley BF, Rogers MA. Testosterone, growth hormone and IGF-I responses to acute and chronic resistive exercise in men aged 55–70 years. Int J Sports Med 1995; 16: 445–450.

40 - Pyka G, Wiswell RA, Marcus R. Age-dependent effect of resistance exercise on growth hormone secretion in people. J Clin Endocrinol Metab 1992; 75: 404–407.

41 - Grobet L, Poncelet D, Royo LJ, Brouwers B, Pirottin D, Michaux C, Menissier F, Zanotti M, Dunnr S, Georges M. Molecular definition of anallelic series of mutations disrupting the myostatin function and causing double-muscling in cattle. Mamm Genome 1998; 9 :210–213.

42 - Jorgensen JO, Vahl N, Hansen TB, Fisker S, Hagen C, Christiansen JS. Influence of growth hormone and androgens on body composition in adults. Horm Res 1996; 45: 94–98.

43 - Lucidi P, Lauteri M, Laureti S, Celleno R, Santoni S, Volpi E, Angeletti G,

Santeusanio F, De Feo P. A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adult. J Clin Endocrinol Metab 1998; 83: 353–357.

44 - Wolfe J. Growth hormone: a physiological fountain of youth? JAMA 1998; 1: 9-25.

45 - Jorgensen JO, Christiansen JS 1993 Brave new senescence: GH in adults. Lancet 341:1247–1248.

46 - Holloway L, Butterfield G, Hintz R, Gesundheit N, Marcus R. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994; 447–479.

47 - Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, et al. The Australian multicenter trial of growth hormone (GH) treatment in GHdeficient adults. J Clin Endocrinol Metab 1998; 83: 107–116.

48 - Janssen YJH, Deurenberg P, Roelfsema F. Using dilution techniques and multi-frequency bioelectrical impedance to assess both total body water and extracellular water at baseline and during rhGH treatment in GH deficient adults. J Clin Endocrinol Metab 1997; 82: 3349–3355.

49 - Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerblad M, Manhem P, Rosen T, Thoren M, Bengtsson BA. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. J Clin Endocrinol Metab 1996; 81: 1575–1581.

50 - Vahl N, Moller N, Lauritzen T, Christiansen JS, Jorgensen JOL. Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. J Clin Endocrinol Metab 1997; 82: 1–7.

51 - Merriam GR, Buchner DM, Prinz PN, Schwartz RS, Vitiello V. Potential applications of GH secretagogues in the evaluation and treatment of the age-related decline in growth hormone secretion. Endocrine 1997; 7 :49–52.

52 - Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone releasing peptides. Eur J Endocrinol 1997; 136: 445–460.

53 - Kern W, Schiefer B, Schwarzenburg J, Stange EF, Born J, Fehm HL. Evidence for central nervous effects of corticotropin-releasing hormone on gastric acid secretion in humans. Neuroendocrinology 1997; 65: 291–298.

54 - Marcus R, Butterfield G, Holloway L, et al. Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol and Metab 1990; 70: 519-27.

55 - Colao A, Somma CD, Stefano S, Filippella M, Pivonello R, Lombardi G. Effect of Growth Hormone and/or Testosterone Replacement on the Prostate in GH-Deficient Adult Patients. J  Clin Endocrinol Metab 2003; 88(1):88–94.

56 - Rudman D, Feller AG, Nagraj HS, et al. Effect of growth hormones in men over 60 years old. N Engl J Med 1990;323:1-6.

57 - Blackman MR, Sorkin JD, Munzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002; 288: 2282-92.

58 - Leung KC, Doyle N, Ballesteros M, et al. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci U S A 2003; 100: 1016-21.

59 - Weissberger AJ, Ho KKY, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone secretion, insulin-like growth factor I and GH binding protein in post-menopausal women. J Clin Endocrinol Metab 1991; 72: 374-81.

60 - Lange KH, Isaksson F, Juul A, et al. Growth hormone enhances effects of endurance training on oxidative muscle metabolism in elderly women. Am J Physiol Endocrinol Metab 2000; 279: E 989-96.

61 - Cohn L, Feller AG, Draper MW, et al. Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-1 concentrations. Clin Endocrinol 1993; 39: 417-25.

62 - Ho KY, Weissberger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism 1990; 39: 133-7.

63 - Caidahl K, Eden S, Bengtsson B. Cardiovascular and renal effects of growth hormone. Clin Endocrinol 1994; 40: 393- 400.

64 - Hennessey JV, Chromiak JA, DellaVentura S, et al. Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people. J Am Geriatr Soc 2001; 49: 852-8.

65 - Rosen CJ, Bilezikian JP. Clinical review 123: anabolic therapy for osteoporosis. J Clin Endocrinol Metab 2001; 86: 957-64.

66 - Holmes SJ, Whitehouse RW, Swindell R, et al. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficien cy. Clin Endocrinol 1995; 42: 627-33.

67 - Johannsson G, Rosen T, Bosaeus I, et al. Long term growth hormone treatment increases bone mineral content and density in patients with adult-onset growth hormone deficiency. J Clin Endocrinol Metab 1996; 81: 2865-73.

68 - Weissberger AJ, Anastasiadis AD, Sturgess I, et al. Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement. Clin Endocrinol (Oxf) 2003; 58: 99-107.

69 - Rosen T, Johansen G, Johansen J, et al. Consequences of growth hormone hormone deficiency in adults and the benefits of recombinant human growth hormone tratment. Horm Res.1995; 43:93-99.

70 - Toogood A. The Somatopause: an Indication for Growth Hormone Therapy? Treat Endocrinol 2004; 3 (4): 201-209.

71 - Drake WM, Howell SJ, Monson JP, et al. Optimizing GH therapy in adults and children. Endocr Rev 2001; 22: 425-50.

72 - Chan J, Stampfer M, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-6.

73 - Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620-5.

74 - Cohen P, Clemmons DR, Rosenfeld RG. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 2000; 10: 297-305.


IMPORTANTE

  •  Procure o seu médico para diagnosticar doenças, indicar tratamentos e receitar remédios. 
  • As informações disponíveis no site da Dra. Shirley de Campos possuem apenas caráter educativo.
Publicado por: Dra. Shirley de Campos
versão para impressão

Desenvolvido por: Idelco Ltda.
© Copyright 2003 Dra. Shirley de Campos